In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 3, 2001, Pages 723-735

  Yamazaki, Masayo ^a   Neway, William E ^a   Ohe, Tomoyuki ^a,b   Chen, I Wu ^a   Rowe, Janice F ^a   Hochman, Jerome H ^a   Chiba, Masato ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL STRAIN KB; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; EPITHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SPECIES DIFFERENCE; SWINE; TRANSCYTOSIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; HUMANS; KB CELLS; MICE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0035119989     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
2. Biochemical, cellular and pharmacological aspects of the multidrug transporter
3. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
4. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
5. 3H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand
6. 3H]-(±)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors
7. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines
8. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
9. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
10. Transporters and drug disposition
11. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
12. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) again broad-spectrum β-lactamase-and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
13. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
14. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity
15. Antiestrogens and steroid hormones: Substrates of the human P-glycoprotein
16. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins
17. P-glycoprotein, a gatekeeper in the blood-brain barrier
18. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
19. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
20. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
21. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
22. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs
23. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators
24. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
25. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
26. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism
27. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
28. Differential transport properties of two mdr gene products are distinguished by progesterone
29. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions